Journal: Molecular cell

Article Title: p300-Mediated Lysine 2-Hydroxyisobutyrylation Regulates Glycolysis

doi: 10.1016/j.molcel.2018.04.011

Figure Lengend Snippet: Key Resources Table

Article Snippet: pCMV3-HA-ENO1 , Sino Biological , Cat# HG11554-NY.

Techniques: Recombinant, shRNA, Clone Assay, Synthesized, Activity Assay, Mutagenesis, Mass Spectrometry, Western Blot, Sequencing, Software

Journal: Oncotarget

Article Title: Serological proteome analysis approach-based identification of ENO1 as a tumor-associated antigen and its autoantibody could enhance the sensitivity of CEA and CYFRA 21-1 in the detection of non-small cell lung cancer

doi: 10.18632/oncotarget.17067

Figure Lengend Snippet: Mass spectrum result for 47 KDa protein

Article Snippet: cDNA encoding human ENO1 was amplified by PCR from a commercial plasmid PMD18T-ENO1 (Sino Biological Inc., Beijing, China).

Techniques:

Journal: Oncotarget

Article Title: Serological proteome analysis approach-based identification of ENO1 as a tumor-associated antigen and its autoantibody could enhance the sensitivity of CEA and CYFRA 21-1 in the detection of non-small cell lung cancer

doi: 10.18632/oncotarget.17067

Figure Lengend Snippet: (A, D-F) Comparison of autoantibody level of anti-ENO1 in NSCLC patients and subgroups (stage, histology and metastasis) compared to normal individuals. Box and Whisker plots for serum level of anti-ENO1 in patients and normal individuals. The line within the box marks the median, and the 25 th and 75 th percentiles are presented by the edges of the area, which is known as inter-quartile range (IQR). The bars indicate 1.5 times of the IQR from upper or lower percentiles. P : Mann-Whitney test. (B) Frequency of anti-ENO1 autoantibody in NSCLC patients and normal individuals. P : χ 2 test. (C): ROC curve of autoantibody to ENO1.

Article Snippet: cDNA encoding human ENO1 was amplified by PCR from a commercial plasmid PMD18T-ENO1 (Sino Biological Inc., Beijing, China).

Techniques: Whisker Assay, MANN-WHITNEY

Journal: Oncotarget

Article Title: Serological proteome analysis approach-based identification of ENO1 as a tumor-associated antigen and its autoantibody could enhance the sensitivity of CEA and CYFRA 21-1 in the detection of non-small cell lung cancer

doi: 10.18632/oncotarget.17067

Figure Lengend Snippet: Anti-ENO1 level and area under the curve in different characteristics in validation set

Article Snippet: cDNA encoding human ENO1 was amplified by PCR from a commercial plasmid PMD18T-ENO1 (Sino Biological Inc., Beijing, China).

Techniques:

Journal: Oncotarget

Article Title: Serological proteome analysis approach-based identification of ENO1 as a tumor-associated antigen and its autoantibody could enhance the sensitivity of CEA and CYFRA 21-1 in the detection of non-small cell lung cancer

doi: 10.18632/oncotarget.17067

Figure Lengend Snippet: Multivariable logistic analyses for anti-ENO1 and various diagnostic factors in NSCLC patients

Article Snippet: cDNA encoding human ENO1 was amplified by PCR from a commercial plasmid PMD18T-ENO1 (Sino Biological Inc., Beijing, China).

Techniques: Diagnostic Assay

Journal: Oncotarget

Article Title: Serological proteome analysis approach-based identification of ENO1 as a tumor-associated antigen and its autoantibody could enhance the sensitivity of CEA and CYFRA 21-1 in the detection of non-small cell lung cancer

doi: 10.18632/oncotarget.17067

Figure Lengend Snippet: (A and B) show autoantibody level of anti-ENO1 has no correlation with CEA (A) and CYFRA 21-1 (B) in NSCLC patients. P : Spearman's test, R : Correlation coefficient in Spearman's test. (C) : frequency/sensitivity of anti-ENO1, CEA, CYFRA 21-1 and their combination in NSCLC patients.

Article Snippet: cDNA encoding human ENO1 was amplified by PCR from a commercial plasmid PMD18T-ENO1 (Sino Biological Inc., Beijing, China).

Techniques:

Journal: Oncotarget

Article Title: Serological proteome analysis approach-based identification of ENO1 as a tumor-associated antigen and its autoantibody could enhance the sensitivity of CEA and CYFRA 21-1 in the detection of non-small cell lung cancer

doi: 10.18632/oncotarget.17067

Figure Lengend Snippet: Mass spectrum result for 47 KDa protein

Article Snippet: cDNA encoding human ENO1 was amplified by PCR from a commercial plasmid PMD18T-ENO1 (Sino Biological Inc., Beijing, China).

Techniques:

Journal: Oncotarget

Article Title: Serological proteome analysis approach-based identification of ENO1 as a tumor-associated antigen and its autoantibody could enhance the sensitivity of CEA and CYFRA 21-1 in the detection of non-small cell lung cancer

doi: 10.18632/oncotarget.17067

Figure Lengend Snippet: (A, D-F) Comparison of autoantibody level of anti-ENO1 in NSCLC patients and subgroups (stage, histology and metastasis) compared to normal individuals. Box and Whisker plots for serum level of anti-ENO1 in patients and normal individuals. The line within the box marks the median, and the 25 th and 75 th percentiles are presented by the edges of the area, which is known as inter-quartile range (IQR). The bars indicate 1.5 times of the IQR from upper or lower percentiles. P : Mann-Whitney test. (B) Frequency of anti-ENO1 autoantibody in NSCLC patients and normal individuals. P : χ 2 test. (C): ROC curve of autoantibody to ENO1.

Article Snippet: cDNA encoding human ENO1 was amplified by PCR from a commercial plasmid PMD18T-ENO1 (Sino Biological Inc., Beijing, China).

Techniques: Whisker Assay, MANN-WHITNEY

Journal: Oncotarget

Article Title: Serological proteome analysis approach-based identification of ENO1 as a tumor-associated antigen and its autoantibody could enhance the sensitivity of CEA and CYFRA 21-1 in the detection of non-small cell lung cancer

doi: 10.18632/oncotarget.17067

Figure Lengend Snippet: Anti-ENO1 level and area under the curve in different characteristics in validation set

Article Snippet: cDNA encoding human ENO1 was amplified by PCR from a commercial plasmid PMD18T-ENO1 (Sino Biological Inc., Beijing, China).

Techniques:

Journal: Oncotarget

Article Title: Serological proteome analysis approach-based identification of ENO1 as a tumor-associated antigen and its autoantibody could enhance the sensitivity of CEA and CYFRA 21-1 in the detection of non-small cell lung cancer

doi: 10.18632/oncotarget.17067

Figure Lengend Snippet: Multivariable logistic analyses for anti-ENO1 and various diagnostic factors in NSCLC patients

Article Snippet: cDNA encoding human ENO1 was amplified by PCR from a commercial plasmid PMD18T-ENO1 (Sino Biological Inc., Beijing, China).

Techniques: Diagnostic Assay

Journal: Oncotarget

Article Title: Serological proteome analysis approach-based identification of ENO1 as a tumor-associated antigen and its autoantibody could enhance the sensitivity of CEA and CYFRA 21-1 in the detection of non-small cell lung cancer

doi: 10.18632/oncotarget.17067

Figure Lengend Snippet: (A and B) show autoantibody level of anti-ENO1 has no correlation with CEA (A) and CYFRA 21-1 (B) in NSCLC patients. P : Spearman's test, R : Correlation coefficient in Spearman's test. (C) : frequency/sensitivity of anti-ENO1, CEA, CYFRA 21-1 and their combination in NSCLC patients.

Article Snippet: cDNA encoding human ENO1 was amplified by PCR from a commercial plasmid PMD18T-ENO1 (Sino Biological Inc., Beijing, China).

Techniques: